7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Jaw Diseases D007571 4 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Labyrinthitis D007762 2 associated lipids
Legg-Calve-Perthes Disease D007873 1 associated lipids
Leukemia D007938 74 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Lymphocytosis D008218 2 associated lipids
Macular Degeneration D008268 5 associated lipids
Malocclusion D008310 3 associated lipids
Malocclusion, Angle Class I D008311 1 associated lipids
Mandibular Diseases D008336 5 associated lipids
Mandibular Injuries D008338 1 associated lipids
Measles D008457 3 associated lipids
Mitral Valve Insufficiency D008944 4 associated lipids
Mitral Valve Stenosis D008946 3 associated lipids
Fluorosis, Dental D009050 1 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Multiple Myeloma D009101 13 associated lipids
Musculoskeletal Diseases D009140 2 associated lipids
Cardiomyopathies D009202 10 associated lipids
Myocardial Infarction D009203 21 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Obesity, Morbid D009767 8 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Osteitis D010000 10 associated lipids
Osteitis Deformans D010001 3 associated lipids
Osteoarthritis D010003 4 associated lipids
Osteolysis D010014 8 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteopetrosis D010022 1 associated lipids
Osteoporosis D010024 12 associated lipids
Osteosclerosis D010026 2 associated lipids
Otosclerosis D010040 2 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Respirovirus Infections D010253 3 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Periapical Diseases D010483 4 associated lipids
Periapical Granuloma D010484 3 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Pericardial Effusion D010490 2 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Periodontal Diseases D010510 15 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Periostitis D010522 1 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Polycythemia Vera D011087 13 associated lipids
Prediabetic State D011236 1 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Progeria D011371 3 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Prosthesis Failure D011475 1 associated lipids
Radicular Cyst D011842 2 associated lipids
Rheumatic Fever D012213 1 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Root Resorption D012391 2 associated lipids
Rupture, Spontaneous D012422 1 associated lipids
Sarcoma, Ewing D012512 2 associated lipids
Osteosarcoma D012516 50 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Sclerosis D012598 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomatitis D013280 14 associated lipids
Synovitis D013585 15 associated lipids
Synovitis, Pigmented Villonodular D013586 1 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Temporomandibular Joint Disorders D013705 4 associated lipids
Thinness D013851 11 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Tinnitus D014012 4 associated lipids
Tooth Migration D014085 2 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Resorption D014091 1 associated lipids
Uremia D014511 33 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Vascular Diseases D014652 16 associated lipids
Vision Disorders D014786 10 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Wounds and Injuries D014947 20 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Bénard J [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? 2000 Bull Cancer pmid:11184451
Yamashita T et al. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. 2000 Endocrinology pmid:10614667
Hofbauer LC et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. 2000 J. Bone Miner. Res. pmid:10646108
Kanzawa M et al. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. 2000 Eur. J. Endocrinol. pmid:10822231
Mukohyama H et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. 2000 Biochem. Biophys. Res. Commun. pmid:10777696
Atkins GJ et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. 2000 J. Bone Miner. Res. pmid:10780856
Thompson SW and Tonge D Bone cancer gain without the pain. 2000 Nat. Med. pmid:10802700
Honore P et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. 2000 Nat. Med. pmid:10802707
Onyia JE et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. 2000 J. Bone Miner. Res. pmid:10804015
Bateman TA et al. Osteoprotegerin mitigates tail suspension-induced osteopenia. 2000 Bone pmid:10773583
Malyankar UM et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. 2000 J. Biol. Chem. pmid:10811631
Thirunavukkarasu K et al. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. 2000 J. Biol. Chem. pmid:10833509
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Medscape Womens Health pmid:10792853
Fata JE et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. 2000 Cell pmid:11051546
Miyamoto N et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. 2000 J. Orthop. Res. pmid:11052502
Kinpara K et al. Osteoclast differentiation factor in human osteosarcoma cell line. 2000 J Immunoassay pmid:11071251
Kaneda T et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. 2000 J. Immunol. pmid:11035059
Miyamoto T et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. 2000 Blood pmid:11110710
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 Bone pmid:11113385
Takayanagi H et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. 2000 Nature pmid:11117749
Mancini L et al. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. 2000 Biochem. Biophys. Res. Commun. pmid:11118297
Lee ZH et al. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. 2000 Mol. Pharmacol. pmid:11093794
Kong YY and Penninger JM Molecular control of bone remodeling and osteoporosis. 2000 Exp. Gerontol. pmid:11121682
Shalhoub V et al. Characterization of osteoclast precursors in human blood. 2000 Br. J. Haematol. pmid:11122091
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 J. Bone Miner. Res. pmid:11127193
Sakuma Y et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 Infect. Immun. pmid:11083800
Riggs BL The mechanisms of estrogen regulation of bone resorption. 2000 J. Clin. Invest. pmid:11086020
Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 Endocrinology pmid:10965921
Yasuda H [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. 2000 Seikagaku pmid:10967683
Teitelbaum SL Bone resorption by osteoclasts. 2000 Science pmid:10968780
Lacey DL et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. 2000 Am. J. Pathol. pmid:10934148
Quinn JM et al. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. 2000 J. Bone Miner. Res. pmid:10934644
Min H et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. 2000 J. Exp. Med. pmid:10952716
Shiba H et al. Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. 2000 Mech. Ageing Dev. pmid:10958924
López FJ New approaches to the treatment of osteoporosis. 2000 Curr Opin Chem Biol pmid:10959765
Nakashima T et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. 2000 Biochem. Biophys. Res. Commun. pmid:10973797
Itoh K et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. 2000 J. Bone Miner. Res. pmid:10976996
Schinke T and Karsenty G Vascular calcification--a passive process in need of inhibitors. 2000 Nephrol. Dial. Transplant. pmid:10978374
Lorenzo J Interactions between immune and bone cells: new insights with many remaining questions. 2000 J. Clin. Invest. pmid:10995785
Teng YT et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. 2000 J. Clin. Invest. pmid:10995794
Børset M et al. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. 2000 Blood pmid:11001907
Hofbauer LC and Heufelder AE Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. 2000 J. Clin. Endocrinol. Metab. pmid:10902778
Rani CS and MacDougall M Dental cells express factors that regulate bone resorption. 2000 Mol. Cell Biol. Res. Commun. pmid:10860862
Huang L et al. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. 2000 Am. J. Pathol. pmid:10702390
Capparelli C et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. 2000 Cancer Res. pmid:10706080
Makhluf HA et al. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. 2000 Biochem. Biophys. Res. Commun. pmid:10679262
Merewether LA et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. 2000 Arch. Biochem. Biophys. pmid:10683254
Ross FP RANKing the importance of measles virus in Paget's disease. 2000 J. Clin. Invest. pmid:10712423
Tricot G New insights into role of microenvironment in multiple myeloma. 2000 Lancet pmid:10675068
Takayanagi H et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. 2000 Arthritis Rheum. pmid:10693864
Itonaga I et al. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. 2000 Ann. Rheum. Dis. pmid:10627423
Chikatsu N et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. 2000 Biochem. Biophys. Res. Commun. pmid:10631114
Takami M et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. 2000 Endocrinology pmid:11108286
Gori F et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. 2000 Endocrinology pmid:11108292
Clohisy DR et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. 2000 J. Orthop. Res. pmid:11192258
Aubin JE and Bonnelye E Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 Osteoporos Int pmid:11193242
Wise GE et al. Osteoprotegerin and osteoclast differentiation factor in tooth eruption. 2000 J. Dent. Res. pmid:11201042
Kotake S et al. [Molecular mechanism of bone metabolism]. 2000 Nippon Naika Gakkai Zasshi pmid:11215116
Kanematsu M et al. [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. 2000 Biol. Sci. Space pmid:12561872
Kikuchi T et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. 2001 J. Immunol. pmid:11207318
O'Brien EA et al. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. 2001 Bone pmid:11182380
Zhang YH et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. 2001 J. Biol. Chem. pmid:11032840
Goltzman D Osteolysis and cancer. 2001 J. Clin. Invest. pmid:11375409
Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. 2001 J. Clin. Invest. pmid:11375413
Kostenuik PJ and Shalhoub V Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. 2001 Curr. Pharm. Des. pmid:11375772
Lories RJ and Luyten FP Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 Clin. Rheumatol. pmid:11254237
Wan M et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. 2001 J. Biol. Chem. pmid:11139569
Browner WS et al. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. 2001 J. Clin. Endocrinol. Metab. pmid:11158021
Hofbauer LC and Heufelder AE [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. 2001 Dtsch. Med. Wochenschr. pmid:11233883
Bolon B et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. 2001 Mol. Ther. pmid:11237676
Sasaki N et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. 2001 Nephrol. Dial. Transplant. pmid:11239019
Takeuchi T et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. 2001 Biochem. Pharmacol. pmid:11239501
Mori K et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. 2001 Cell. Immunol. pmid:11243701
Hofbauer LC et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162519
Brändström H et al. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. 2001 Biochem. Biophys. Res. Commun. pmid:11162596
Wuyts W et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. 2001 Bone pmid:11165949
Michigami T et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. 2001 Cancer Res. pmid:11245477
Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. 2001 Scand. J. Rheumatol. pmid:11578019
Sakai E et al. Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. 2001 J. Biochem. pmid:11726283
Quinn JM et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. 2001 J. Bone Miner. Res. pmid:11585342
Choi SJ et al. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. 2001 J. Bone Miner. Res. pmid:11585344
Miyamoto T et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. 2001 Blood pmid:11588053
Pearse RN et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11562486
Kostenuik PJ et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. 2001 Endocrinology pmid:11564687
Marco-Mingot M et al. Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. 2001 Clin. Genet. pmid:11531977
Raffai RL et al. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11553788
Hocking LJ et al. Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. 2001 Am. J. Hum. Genet. pmid:11555792
Hofbauer LC et al. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. 2001 Cancer pmid:11505389
Hofbauer LC and Heufelder AE Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. 2001 J. Mol. Med. pmid:11485016
Wise GE et al. Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. 2001 Clin Anat pmid:11301468
Atkins GJ et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 2001 Bone pmid:11336917
Komine M et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. 2001 Bone pmid:11344046
Chen D et al. ELISA methodology for detection of modified osteoprotegerin in clinical studies. 2001 Clin. Chem. pmid:11274028
Collin-Osdoby P et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. 2001 J. Biol. Chem. pmid:11274143
Brown JM et al. Osteoprotegerin and rank ligand expression in prostate cancer. 2001 Urology pmid:11306358
Fukagawa M et al. [PTH and bone metabolism in chronic dialysis patients]. 2001 Rinsho Byori pmid:11307321
Horowitz MC et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. 2001 Cytokine Growth Factor Rev. pmid:11312114
Lin DL et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. 2001 Prostate pmid:11351351
Sparks AB et al. Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. 2001 Calcif. Tissue Int. pmid:11351498
Disthabanchong S and González EA Regulation of bone cell development and function: implication for renal osteodystrophy. 2001 J. Investig. Med. pmid:11352181

Table of Content